Product Description
Tranylcypromine is used to treat certain types of depression. It belongs to the group of medicines called monoamine oxidase inhibitors (MAOI). This medicine works by blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. (Sourced from: https://www.mayoclinic.org/drugs-supplements/tranylcypromine-oral-route/side-effects/drg-20073226?p=1)
Mechanisms of Action: MAO Inhibitor, LSD1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Brazil | Canada | Croatia | Egypt | Germany | India | Ireland | Netherlands | New Zealand | Saudi Arabia | Spain | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/09/2025 |
News Article |
Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies |
|
07/10/2024 |
News Article |
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics |
|
04/15/2024 |
News Article |
Acorda Therapeutics Announces Delisting from Nasdaq |
|
04/03/2024 |
News Article |
Acorda Therapeutics Announces Nasdaq Delisting Notification |